Načítá se...
Nanocarriers and nonviral methods for delivering antiangiogenic factors for glioblastoma therapy: the story so far
Angiogenesis, the formation of new blood vessels, is an essential component of glioblastoma (GB) progression. The development of angiogenesis inhibitor therapy, including treatments targeting vascular endothelial growth factor (VEGF) in particular, raised new hopes for the treatment of GB, but no Ph...
Uloženo v:
| Vydáno v: | Int J Nanomedicine |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove Medical Press
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6461002/ https://ncbi.nlm.nih.gov/pubmed/31040671 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S194858 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|